BRIEF-Gemini reports Q1 net loss per share of $0.04
* Now expecting revenue for 2017 to be less than 2016 but expects activity to pick up in second half of 2017 into 2018 Source text for Eikon: Further company coverage:
Alnylam Pharmaceuticals Inc said a U.S. federal court has ruled that it could sue Canada's Tekmira Pharmaceuticals Corp for infringing patents on lipid nanoparticle technology exclusively licensed to Alnylam.
Alnylam also said it filed a similar lawsuit in Canada.
Alnylam had alleged that Tekmira provided its molecules to pharmaceutical collaborators despite having an exclusive agreement licensing them to Alnylam to use in its RNA therapy.
The company said the U.S. federal court in Massachusetts denied Tekmira's motions to dismiss certain claims by Alnylam.
Alnylam shares closed at $19.38 on the Nasdaq on Tuesday.
(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)
* Ironhorse announces Q1 2017 financial and operating results
* AT&T announces IBEW-represented employees vote to ratify midwest wireline agreement